title: Successful treatment of non-small cell lung cancer with gefitinib after erlotinib-induced severe eyelid erosion: Two case reports.
abstract: Gefitinib and erlotinib are first-generation, small, molecular inhibitors of the epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI). Even as these drugs have led to a paradigm shift in the treatment of advanced non-small cell lung cancer (NSCLC), drug-induced adverse effects are commonly seen. We experienced two cases of NSCLC patients who developed erlotinib-induced eyelid erosion and were then successfully treated with gefitinib, without recurrence of toxicity or disease progression. As far as we had investigated, this is the first report documenting the successful cases treated with gefitinib after erlotinib-related severe eyelid erosion.
authors.affiliation: Department of Pulmonology, Kameda Medical Center, Kamogawa, Chiba; Department of Internal Medicine, Division of Respiratory Medicine and Allergology, Aichi Medical University School of Medicine, Aichi, Japan.
authors.forename: Nobuhiro
authors.initials: N
authors.lastname: Asai
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Ohkuni
authors.forename: Etsuro
authors.initials: E
authors.lastname: Yamaguchi
authors.forename: Norihiro
authors.initials: N
authors.lastname: Kaneko
mesh_terms: D000368:Aged; D002289:Carcinoma, Non-Small-Cell Lung / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D000069347:Erlotinib Hydrochloride / Q000008:administration & dosage / Q000009:adverse effects*; D005141:Eyelid Diseases / Q000139:chemically induced / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D000077156:Gefitinib; D006801:Humans; D008297:Male; D008875:Middle Aged; D011799:Quinazolines / Q000008:administration & dosage*
chemical_list: D011799:Quinazolines; D000069347:Erlotinib Hydrochloride; D000077156:Gefitinib